These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31519579)

  • 1. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
    Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
    Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
    Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Transl Oncol; 2019 Sep; 12(9):1257-1263. PubMed ID: 31299622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
    Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.